Advances in the management of melanoma: Targeted therapy, immunotherapy and future directions

Expert Review of Anticancer Therapy

Volumn 12, Issue 11, 2012, Pages 1437-1448

  Dean, Emma ^a   Lorigan, Paul ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

anti CTLA 4; BRAF; dabrafenib; immunotherapy; ipilimumab; melanoma; PD 1; trametinib; vemurafenib

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AD 6244; ALPHA INTERFERON; B RAF KINASE INHIBITOR; BEVACIZUMAB; BMS 936559; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DABRAFENIB; DACARBAZINE; GDC 0973; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMATINIB; IMMUNOMODULATING AGENT; IPILIMUMAB; LGX 818; MELANOMA ANTIGEN 3 VACCINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; NIVOLUMAB; PEGINTERFERON ALPHA2B; PLACEBO; SELUMETINIB; TEMOZOLOMIDE; TICILIMUMAB; TRAMETINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB;

ACTINIC KERATOSIS; ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; ARTHRALGIA; BLURRED VISION; BRAIN METASTASIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CHILL; CHORIORETINOPATHY; DERMATITIS; DIARRHEA; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG MEGADOSE; DRUG TARGETING; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FATIGUE; FEVER; GENE MUTATION; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART VENTRICLE FAILURE; HUMAN; HYPERKERATOSIS; KERATOACANTHOMA; LIVER FUNCTION TEST; LIVER TOXICITY; MELANOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL EDEMA; PHOTOSENSITIVITY; REVIEW; SIDE EFFECT; SKIN DEFECT; SKIN MANIFESTATION; SKIN PAPILLOMA; SQUAMOUS CELL CARCINOMA; SYSTEMIC THERAPY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; INDOLES; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84871336035     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.124     Document Type: Review

References (107)

1. Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 14(10), 2666-2673 (1996).
2. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14(1), 7-17 (1996).
3. Korn EL, Liu PY, Lee SJ et al. Meta-analysis of Phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future Phase II trials. J. Clin. Oncol. 26(4), 527-534 (2008).
4. Crosby T, Fish R, Coles B et al. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst. Rev. 2000(2), CD001215 (2000).
5. Hill GJ 2nd, Krementz ET, Hill HZ. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer 53(6), 1299-1305 (1984).
6. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17(7), 2105-2116 (1999).
7. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol. 19(15), 3477-3482 (2001).
8. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417(6892), 949-954 (2002).
9. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353(20), 2135-2147 (2005).
10. Si L, Kong Y, Xu X et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur. J. Cancer 48(1), 94-100 (2012).
11. Jakob JA, Bassett RL Jr, Ng CS et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118(16), 4014-4023 (2012).
12. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64(19), 7099-7109 (2004).
13. Eisen T, Ahmad T, Flaherty KT et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer 95(5), 581-586 (2006).
14. McDermott DF, Sosman JA, Gonzalez R et al. Double-blind randomized Phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J. Clin. Oncol. 26(13), 2178-2185 (2008).
15. Hauschild A, Agarwala SS, Trefzer U et al. Results of a Phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 27(17), 2823-2830 (2009).
16. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363(9), 809-819 (2010).
17. Flaherty KT, Lee SJ, Schuchter LM. Final results of E2603: a double-blind, randomized Phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma. J. Clin. Oncol. 28(15), Abstract 8511 (2010).
18. Ribas A, Kim KB, Schuchter LM. BRIM-2: an open-label, multicenter Phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J. Clin. Oncol. 29, Abstract 8509 (2011).
19. Chapman PB, Hauschild A, Robert C et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507-2516 (2011).
20. Chapman PB, Hauschild A, Robert C. Updated overall survival (OS) results for BRIM-3, a Phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600Emutated melanoma. J. Clin. Oncol. 30, Abstract 8502 (2012).
21. Su F, Viros A, Milagre C et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366(3), 207-215 (2012).
22. Zimmer L, Hillen U, Livingstone E et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J. Clin. Oncol. 30(19), 2375-2383 (2012).
23. Kefford R. Phase I/II study of dabrafenib, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J. Clin. Oncol. J. Clin. Oncol. 28, Abstract 8503 (2010).
24. Hauschild A, Grob JJ, Demidov LV et al. Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma. J. Clin. Oncol. 30, Abstract LBA 8500 (2012).
25. Kirkwood JM. BREAK-MB: a Phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/K mutation-positive melanoma with brain metastases (mets). J. Clin. Oncol. 302, Abstract 8501 (2012).
26. Dummer R, Rinderknecht J, Goldinger SM et al. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. J. Clin. Oncol. 29, Abstract
27. Menzies AM, Visintin L, Chatfield MD et al. BRAF mutation by age-decade and body mass index in metastatic melanoma. J. Clin. Oncol. 29, Abstract 8507 (2011).
28. Flaherty KT, Robert C, Hersey P et al.; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367(2), 107-114 (2012).
29. Johannessen CM, Boehm JS, Kim SY et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468(7326), 968-972 (2010).
30. Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to B?RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468(7326), 973-977 (2010).
31. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 7(2), 95-106 (2007).
32. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011).
33. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
34. Camacho LH, Antonia S, Sosman J et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol. 27(7), 1075-1081 (2009).
35. Kirkwood JM, Lorigan P, Hersey P et al. Phase II trial of tremelimumab (CP?675,206) in patients with advanced refractory or relapsed melanoma. Clin. Cancer Res. 16(3), 1042-1048 (2010).
36. Ribas A, Hauschild A, Kefford R et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J. Clin. Oncol. 26, Abstract LBA9011 (2008).
37. Wolchok JD, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, Phase 2, dose-ranging study. Lancet Oncol. 11(2), 155-164 (2010).
38. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A metaanalysis of the randomised trials. Cancer Treat. Rev. 29(4), 241-252 (2003).
39. Wheatley K, Ives N, Eggermont A et al. Interferon-? as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. J. Clin. Oncol. 25(18s), Abstract 8526 (2007).
40. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J. Natl Cancer Inst. 102(7), 493-501 (2010).
41. Eggermont AM. Ulceration of primary melanoma and responsiveness to adjuvant interferon therapy: analysis of the adjuvant trials EORTC18952 and EORTC18991 in 2,644 patients. J. Clin. Oncol. 27(15 Suppl.), Abstract 9007 (2009).
42. Louahed J. Expression of defined genes identified by pretreatment tumor profiling: association with clinical responses to the GSK MAGE- A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032-18031). J. Clin. Oncol. 26, Abstract 9045 (2008).
43. Kruit WH. Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: a randomized open-label Phase II study of the EORTC Melanoma Group (16032-18031). J. Clin. Oncol. 26, Abstract 9065 (2008).
44. Kirkwood JM, Dreno B, Hauschild A et al. DERMA Phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in patients with MAGE-A3-positive resected stage III melanoma. J. Clin. Oncol. 29, Abstract TPS232 (2011).
45. Kim KB. Pattern and outcome of disease progression in Phase I study of vemurafenib in patients with metastatic melanoma (MM). J. Clin. Oncol. 29, Abstract 8519 (2011).
46. Wagle N, Emery C, Berger MF et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29(22), 3085-3096 (2011).
47. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531), 876-880 (2001).
48. Ellis LM, Hicklin DJ. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin. Cancer Res. 15(24), 7471-7478 (2009).
49. Montagut C, Sharma SV, Shioda T et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68(12), 4853-4861 (2008).
50. Villanueva J, Vultur A, Lee JT et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18(6), 683-695 (2010).
51. Turke AB, Zejnullahu K, Wu YL et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17(1), 77-88 (2010).
52. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827), 1039-1043 (2007).
53. Guix M, Faber AC, Wang SE et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 118(7), 2609-2619 (2008).
54. Paraiso KH, Xiang Y, Rebecca VW et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71(7), 2750-2760 (2011).
55. Infante JR, Falchook GS, Lawrence DP et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J. Clin. Oncol. 29(Suppl.), Abstract CRA8503 (2011).
56. Weber JS, Flaherty KT, Infante JR et al. Updated safety and efficacy results from a Phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFinaive metastatic melanoma. J. Clin. Oncol. 30s, Abstract 8510 (2012).
57. Jackson J, Whitney G, Hamid O et al. Assessment of association between BRAF mutation status in melanoma tumors and response to ipilimumab. J. Clin. Oncol. 29s, Abstract 2587 (2011).
58. Chen H, Liakou CI, Kamat A et al. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc. Natl Acad. Sci. USA 106(8), 2729-2734 (2009).
59. Fu T, He Q, Sharma P. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res. 71(16), 5445-5454 (2011).
60. Simeone E, Gentilcore G, Romano A et al. Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival. J. Clin. Oncol. 30s, Abstract 8573 (2012).
61. Patel SP, Bedikian AY, Papadopoulos NE et al. Ipilimumab plus temozolomide in metastatic melanoma. J. Clin. Oncol. 29s, Abstract 8579 (2011).
62. Di Giacomo AM, Ascierto PA, Pilla L et al. Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)- M1 trial. J. Clin. Oncol. 30s, Abstract 8513 (2012).
63. Maio M, Testori A, Ascierto PA et al. The NIBIT-M1 trial: activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases. J. Clin. Oncol. 30s, Abstract 8529 (2012).
64. Hodi FS, Friedlander PA, Atkins MB et al. A Phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 29s, Abstract 8511 (2011).
65. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8(3), 239-245 (2007).
66. Ribas A. Tumor immunotherapy directed at PD-1. N. Engl. J. Med. 366(26), 2517-2519 (2012).
67. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
68. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167-3175 (2010).
69. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012).
70. Rosenberg SA, Packard BS, Aebersold PM et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319(25), 1676-1680 (1988).
71. Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl Cancer Inst. 86(15), 1159-1166 (1994).
72. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl Acad. Sci. USA 101(Suppl. 2), 14639-14645 (2004).
73. Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23(10), 2346-2357 (2005).
74. Dudley ME. Adoptive cell therapy for patients with melanoma. J. Cancer 2, 360-362 (2011).
75. Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17(13), 4550-4557 (2011).
76. Hong JJ, Rosenberg SA, Dudley ME et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin. Cancer Res. 16(19), 4892-4898 (2010).
77. Joseph RW, Peddareddigari VR, Liu P et al. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin. Cancer Res. 17(14), 4882-4891 (2011).
78. Stroncek DF, Berger C, Cheever MA et al. New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J. Transl. Med. 10, 48 (2012).
79. Dudley ME, Gross CA, Langhan MM et al. CD8+ enriched 'young' tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin. Cancer Res. 16(24), 6122-6131 (2010).
80. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796), 126-129 (2006).
81. Robbins PF, Morgan RA, Feldman SA et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29(7), 917-924 (2011).
82. Ascierto PA, Grimaldi AM, Curti B et al. Future perspectives in melanoma research. Meeting report from the 'Melanoma research: a bridge from Naples to the world. Napoli, December 5th-6th 2011'. J. Transl. Med. 10, 83 (2012).
83. Boni A, Cogdill AP, Dang P et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70(13), 5213-5219 (2010).
84. Wilmott JS, Long GV, Howle JR et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 18(5), 1386-1394 (2012).
85. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24(26), 4340-4346 (2006).
86. Woodman SE, Trent JC, Stemke-Hale K et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol. Cancer Ther. 8(8), 2079-2085 (2009).
87. Beadling C, Jacobson-Dunlop E, Hodi FS et al. KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res. 14(21), 6821-6828 (2008).
88. Kim KB, Eton O, Davis DW et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br. J. Cancer 99(5), 734-740 (2008).
89. Wyman K, Atkins MB, Prieto V et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106(9), 2005-2011 (2006).
90. Ugurel S, Hildenbrand R, Zimpfer A et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br. J. Cancer 92(8), 1398-1405 (2005).
91. Carvajal RD, Antonescu CR, Wolchok JD et al. KIT as a therapeutic target in metastatic melanoma. JAMA 305(22), 2327-2334 (2011).
92. Guo J, Si L, Kong Y et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-KIT mutation or amplification. J. Clin. Oncol. 29(21), 2904-2909 (2011).
93. Kalinsky K, Lee SJ, Lawrence DP et al. A Phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: an Eastern Cooperative Oncology Group study (E2607). J. Clin. Oncol. 30(Suppl.), Abstract 8522 (2012).
94. Srivastava A, Ralhan R, Kaur J. Angiogenesis in cutaneous melanoma: pathogenesis and clinical implications. Microsc. Res. Tech. 60(2), 208-224 (2003).
95. Varker KA, Biber JE, Kefauver C et al. A randomized Phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann. Surg. Oncol. 14(8), 2367-2376 (2007).
96. González-Cao M, Viteri S, Díaz-Lagares A et al. Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma. Oncology 74(1-2), 12-16 (2008).
97. Perez DG, Suman VJ, Fitch TR et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer 115(1), 119-127 (2009).
98. Kim KB, Sosman JA, Fruehauf JP et al. BEAM: a randomized Phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J. Clin. Oncol. 30(1), 34-41 (2012).
99. Fruehauf J, Lutzky J, McDermott D et al. Multicenter, Phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin. Cancer Res. 17(23), 7462-7469 (2011).
100. Hong DS, Koetz BS, Kurzrock R et al. Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors. J. Clin. Oncol. 28(15 Suppl.), Abstract 2540 (2010).
101. Fruehauf JP, Alger B, Parmakhtiar B et al. A Phase II single arm study of pazopanib and paclitaxel as first-line treatment for unresectable stage III and stage IV melanoma: interim analysis. J. Clin. Oncol. 30(Suppl.), Abstract 8524 (2012).
102. Martin MJ, Hayward R, Viros A, Marais R. Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov. 2(4), 344-355 (2012).
103. Ascierto PA, Marincola FM, Ribas A. Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J. Transl. Med. 9, 196 (2011).
104. Di Giacomo AM, Ascierto PA, Fonsatti E et al. A Phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: the NIBIT-M1 trial. J. Clin. Oncol. 29, Abstract TPS230 (2011).
105. Cancer Research UK. Cancer incidence for common cancers. http://info.cancerresearchuk.org/ cancerstats/incidence/commoncancers (Accessed 4 June 2012)
106. Cancer Research UK. CancerStats key facts: skin cancer. http://publications.cancerresearchuk.org/ downloads/Product/CS-KF-SKIN.pdf (Accessed 4 June 2012)
107. ClinicalTrials.gov. http://clinicaltrials.gov (Accessed 4 June 2012)